Ascendis Common Stock vs Intangible Assets Analysis
ASND Stock | USD 139.70 3.32 2.43% |
Ascendis Pharma financial indicator trend analysis is way more than just evaluating Ascendis Pharma AS prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ascendis Pharma AS is a good investment. Please check the relationship between Ascendis Pharma Common Stock and its Intangible Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Common Stock vs Intangible Assets
Common Stock vs Intangible Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ascendis Pharma AS Common Stock account and Intangible Assets. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Ascendis Pharma's Common Stock and Intangible Assets is -0.13. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Intangible Assets in the same time period over historical financial statements of Ascendis Pharma AS, assuming nothing else is changed. The correlation between historical values of Ascendis Pharma's Common Stock and Intangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Ascendis Pharma AS are associated (or correlated) with its Intangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Intangible Assets has no effect on the direction of Common Stock i.e., Ascendis Pharma's Common Stock and Intangible Assets go up and down completely randomly.
Correlation Coefficient | -0.13 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Common Stock
Intangible Assets
Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.Most indicators from Ascendis Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ascendis Pharma AS current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At present, Ascendis Pharma's Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 7 B, whereas Sales General And Administrative To Revenue is forecasted to decline to 1.92.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 3.9M | 50.5M | 44.1M | 46.3M | Depreciation And Amortization | 16.0M | 17.6M | 18.9M | 19.9M |
Ascendis Pharma fundamental ratios Correlations
Click cells to compare fundamentals
Ascendis Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ascendis Pharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 676.7M | 979.8M | 1.1B | 1.1B | 825.6M | 477.4M | |
Short Long Term Debt Total | 36.6M | 92.0M | 105.0M | 508.4M | 644.3M | 676.5M | |
Total Current Liabilities | 48.0M | 52.8M | 100.4M | 171.3M | 197.3M | 207.2M | |
Total Stockholder Equity | 597.1M | 838.7M | 883.6M | 263.3M | (145.7M) | (138.4M) | |
Property Plant And Equipment Net | 45.1M | 108.1M | 126.0M | 129.1M | 110.6M | 116.2M | |
Current Deferred Revenue | 858K | 363K | 2.6M | 1.2M | 1.1M | 1.0M | |
Net Debt | (561.5M) | (492.5M) | (341.3M) | 63.6M | 252.1M | 264.7M | |
Retained Earnings | (611.3M) | (1.0B) | (1.4B) | (1.9B) | (2.3B) | (2.2B) | |
Accounts Payable | 27.8M | 21.9M | 59.4M | 101.0M | 94.6M | 99.3M | |
Cash | 598.1M | 584.5M | 446.3M | 444.8M | 392.2M | 282.5M | |
Non Current Assets Total | 65.6M | 239.7M | 279.0M | 166.3M | 122.9M | 79.4M | |
Non Currrent Assets Other | 1.5M | 1.4M | 1.8M | 1.9M | 2.1M | 2.2M | |
Cash And Short Term Investments | 598.1M | 718.8M | 682.1M | 735.5M | 399.4M | 339.0M | |
Net Receivables | 5.4M | 387K | 2.2M | 11.9M | 55.8M | 58.6M | |
Common Stock Total Equity | 5.0M | 5.7M | 6.4M | 7.2M | 8.3M | 4.2M | |
Liabilities And Stockholders Equity | 676.7M | 979.8M | 1.1B | 1.1B | 825.6M | 477.4M | |
Non Current Liabilities Total | 31.6M | 88.3M | 100.9M | 655.1M | 773.9M | 812.6M | |
Other Current Assets | 7.6M | 14.0M | 46.2M | 45.4M | 38.6M | 40.5M | |
Total Liab | 79.6M | 141.1M | 201.3M | 826.4M | 971.3M | 1.0B | |
Property Plant And Equipment Gross | 45.1M | 108.1M | 160.0M | 175.7M | 182.2M | 191.3M | |
Total Current Assets | 611.2M | 740.1M | 805.9M | 923.5M | 702.7M | 398.0M | |
Accumulated Other Comprehensive Income | 590.7M | 831.5M | 876.0M | 255.7M | (153.4M) | (145.8M) | |
Short Term Debt | 5.9M | 6.9M | 14.0M | 25.4M | 25.4M | 26.7M | |
Common Stock | 6.4M | 7.2M | 7.6M | 7.7M | 7.7M | 5.2M | |
Other Current Liab | 13.5M | 23.7M | 26.8M | 39.3M | 75.1M | 78.8M | |
Common Stock Shares Outstanding | 46.5M | 50.6M | 54.8M | 56.1M | 56.3M | 39.2M | |
Net Tangible Assets | 593.6M | 833.0M | 878.4M | 258.5M | 297.3M | 374.1M | |
Other Assets | 1.5M | 1.4M | 1.8M | 1.9M | 2.2M | 2.3M | |
Other Stockholder Equity | 611.3M | 698.5M | 872.2M | 252.2M | 2.3B | 2.4B | |
Property Plant Equipment | 45.1M | 108.1M | 126.0M | 129.1M | 148.5M | 155.9M | |
Other Liab | 908K | 3.2M | 3.0M | 172.2M | 198.0M | 207.9M | |
Capital Lease Obligations | 36.6M | 92.0M | 105.0M | 109.2M | 98.8M | 103.7M | |
Inventory | (3.0) | 1.0 | 75.4M | 130.7M | 208.9M | 219.4M | |
Long Term Investments | 15.5M | 124.5M | 145.9M | 30.4M | 5.7M | 5.4M | |
Intangible Assets | 4.4M | 2.2M | 1.8M | 1.3M | 924K | 877.8K | |
Net Invested Capital | 597.1M | 838.7M | 883.6M | 771.7M | 399.8M | 622.0M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.83) | Revenue Per Share 5.595 | Quarterly Revenue Growth (0.24) | Return On Assets (0.28) | Return On Equity (8.18) |
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.